[صفحه اصلی ]   [Archive]  
:: صفحه اصلي :: درباره نشريه :: آخرين شماره :: تمام شماره‌ها :: جستجو :: ثبت نام :: ارسال مقاله :: تماس با ما ::
:: دوره 3، شماره 8 - ( 11-1395 ) ::
برگشت به فهرست نشریات جلد 3 شماره 8 صفحات 46-53
B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease
چکیده:   (87 مشاهده)

The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells.

Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells.

The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies.

متن کامل [PDF 587 kb]   (56 دریافت)    
نوع مطالعه: مروری | موضوع مقاله: تخصصي
ارسال نظر درباره این مقاله
نام کاربری یا پست الکترونیک شما:

کد امنیتی را در کادر بنویسید >



DOI: 10.18869/acadpub.cjns.3.8.46


XML   English Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Lyman D. B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease . Caspian.J.Neurol.Sci. 2017; 3 (8) :46-53
URL: http://cjns.gums.ac.ir/article-1-154-fa.html
B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease . مجله علوم اعصاب کاسپین. 1395; 3 (8) :46-53

URL: http://cjns.gums.ac.ir/article-1-154-fa.html

برگشت به فهرست نشریات دوره 3، شماره 8 - ( 11-1395 )
مجله علوم اعصاب کاسپین Caspian Journal of Neurological Sciences
Persian site map - English site map - Created in 0.997 seconds with 809 queries by yektaweb 3392